It was a pleasure to speak to our Expert Faculty member, Dr Gil Y Melmed (Cedars-Sinai Medical Center, Los Angeles, CA, US), around the ADVANCE and MOTIVATE studies, which investigated risankizumab in the treatment of Crohn’s disease.
- Could you tell us a little about the aims, design and patient populations of the ADVANCE and MOTIVATE studies? (0:10)
- What were the findings of the ADVANCE and MOTIVATE studies? (1:42)
- What questions remain unanswered? (2:47)
Disclosures: Gil Y Melmed has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Share this Video
Related Videos In Inflammatory Bowel Disease
Eamonn Quigley, DDW 2021: Biotherapeutic Blautia Hydrogentrophica in IBS
It was a pleasure to speak with Prof. Eamonn Quigley (Houston Methodist Hospital, Houston, TX, USA) about the phase 2 study of the single-strain live biotherapeutic, Blautia hydrogentrophica (Blautix), currently under investigation in irritable bowel syndrome (IBS). His abstract entitled ‘A Phase 2 Study of Live Biotherapeutic Blautix in Irritable Bowel Syndrome (IBS) Patients with […]
Stefan Schreiber, DDW 2021: Phase 2b/3 SELECTION and Long Term Extension Study Results
It was a pleasure to meet with Prof. Stefan Schreiber (Department of Internal Medicine, University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany) to discuss the results from the Phase 2b/3 SELECTION and Phase 3 SELECTION long term extension study, investigating filgotinib for the treatment of ulcerative colitis. The abstract entitled ‘133: SAFETY ANALYSIS […]
Stefan Schreiber, DDW 2021: True North Study Results
It was a pleasure to meet with Prof. Stefan Schreiber (Department of Internal Medicine, University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany) to discuss the results from the maintenance phase of the True North study, investigating corticosteroid free remission in patients with ulcerative colitis treated with ozanimod. The abstract entitled ‘142: CORTICOSTEROID-FREE REMISSION […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!